PMID- 33378969
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20240226
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 133
DP  - 2021 Jan
TI  - Comprehensive chemical analysis of Zhenshu Tiaozhi formula and its effect on 
      ameliorating glucolipid metabolic disorders in diabetic rats.
PG  - 111060
LID - S0753-3322(20)31252-X [pii]
LID - 10.1016/j.biopha.2020.111060 [doi]
AB  - The present study aims to reveal the compositions of Zhenshu TiaoZhi formula 
      (FTZ) comprehensively, and investigate whether FTZ ameliorate glucolipid 
      metabolism disorders in diabetic rats with the involvement of glucocorticoids in 
      peripheral insulin-sensitive tissues. The fingerprint was established based on 11 
      batches of FTZ samples and chemical compostions of FTZ were identified by ultra 
      performance liquid chromatography-time of flight/mass spectrometry (UPLC-TOF/MS). 
      High-fat diet (HFD) and streptozotocin (STZ) induced diabetic rats were orally 
      administrated with 3 and 6 g/kg body weight of FTZ for 8 weeks. Indices of 
      glucolipid metabolism, including fasting blood glucose (FBG), fasting insulin, 
      insulin resistance index (IRI) and blood lipids were evaluated after treatment of 
      FTZ. The levels of HPA axis hormones were examined. Reverse 
      transcription-polymerase chain reaction (RT-PCR) was adopted to investigate the 
      relative mRNA expressions of 11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1) and 
      glucolipid metabolic indicators. A reference fingerprint was established and 93 
      compounds of FTZ were tentatively identified. In vivo, FTZ treatment exerted 
      antidiabetic and antidyslipidemic effects while decreased the level of 
      corticotropin releasing hormone (CRH). 11beta-HSD1 mRNA showed similar trajectory in 
      both liver, adipose and skeletal muscle tissues, which was up-regulated in 
      diabetic group and ameliorated in FTZ groups. Furthermore, the expressions of 
      glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase (PEPCK) and 
      adipose triglyceride lipase (ATGL) were down-regulated in liver and skeletal 
      muscle. These results elucidated the compositions of FTZ comprehensively and 
      indicated its effect on ameliorating glucolipid metabolism of diabetic rats 
      involved hypothalamus-pituitary-adrenal (HPA) axis homeostasis. Down-regulating 
      11beta-HSD1 in insulin-sensitive tissues might be a potential mechanism of FTZ in 
      treating type 2 diabetes mellitus (T2DM).
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Cai, Jinyan
AU  - Cai J
AD  - Center for Drug Research and Development, Guangdong Pharmaceutical University, 
      Guangzhou, 510006, PR China; Guangdong Metabolic Disease Research Center of 
      Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, 
      Guangzhou, 510006, PR China.
FAU - Zhang, Jingjing
AU  - Zhang J
AD  - Guangdong Metabolic Disease Research Center of Integrated Chinese and Western 
      Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.
FAU - Li, Shanshan
AU  - Li S
AD  - Guangdong Metabolic Disease Research Center of Integrated Chinese and Western 
      Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.
FAU - Lin, Yanduan
AU  - Lin Y
AD  - Center for Drug Research and Development, Guangdong Pharmaceutical University, 
      Guangzhou, 510006, PR China; Guangdong Metabolic Disease Research Center of 
      Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, 
      Guangzhou, 510006, PR China.
FAU - Xiao, Xue
AU  - Xiao X
AD  - Guangdong Metabolic Disease Research Center of Integrated Chinese and Western 
      Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China.
FAU - Guo, Jiao
AU  - Guo J
AD  - Guangdong Metabolic Disease Research Center of Integrated Chinese and Western 
      Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China. 
      Electronic address: gyguoyz@163.com.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Lipids)
RN  - 0 (zhenshu tiaozhi formula)
RN  - 5W494URQ81 (Streptozocin)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
RN  - EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenase Type 1)
RN  - W980KJ009P (Corticosterone)
SB  - IM
MH  - 11-beta-Hydroxysteroid Dehydrogenase Type 1/genetics/metabolism
MH  - Adrenocorticotropic Hormone/blood
MH  - Animals
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Corticosterone/blood
MH  - Corticotropin-Releasing Hormone/blood
MH  - Diabetes Mellitus, Experimental/blood/chemically induced/*drug therapy
MH  - Drugs, Chinese Herbal/*chemistry/*pharmacology
MH  - Hypoglycemic Agents/*analysis/*pharmacology
MH  - Hypolipidemic Agents/isolation & purification/*pharmacology
MH  - Insulin Resistance
MH  - Lipids/*blood
MH  - Male
MH  - Mass Spectrometry
MH  - Rats, Sprague-Dawley
MH  - Streptozocin
MH  - Rats
OTO - NOTNLM
OT  - 11beta-HSD1
OT  - Compositions
OT  - Diabetes mellitus
OT  - FTZ
OT  - Fingerprint
EDAT- 2021/01/01 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/12/31 01:00
PHST- 2020/09/27 00:00 [received]
PHST- 2020/11/16 00:00 [revised]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/31 01:00 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
AID - S0753-3322(20)31252-X [pii]
AID - 10.1016/j.biopha.2020.111060 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2021 Jan;133:111060. doi: 10.1016/j.biopha.2020.111060. Epub 
      2020 Dec 8.